193 related articles for article (PubMed ID: 27510411)
1. Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials.
Bando H; Rubinstein L; Harris P; Yoshino T; Doi T; Ohtsu A; Welch J; Takebe N
Gastric Cancer; 2017 May; 20(3):481-488. PubMed ID: 27510411
[TBL] [Abstract][Full Text] [Related]
2. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.
Garrido-Laguna I; Janku F; Vaklavas C; Falchook GS; Fu S; Hong DS; Naing A; Tsimberidou AM; Wen S; Kurzrock R
Cancer; 2012 Mar; 118(5):1422-8. PubMed ID: 21823111
[TBL] [Abstract][Full Text] [Related]
3. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
Bigot F; Castanon E; Baldini C; Hollebecque A; Carmona A; Postel-Vinay S; Angevin E; Armand JP; Ribrag V; Aspeslagh S; Varga A; Bahleda R; Menis J; Gazzah A; Michot JM; Marabelle A; Soria JC; Massard C
Eur J Cancer; 2017 Oct; 84():212-218. PubMed ID: 28826074
[TBL] [Abstract][Full Text] [Related]
4. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials.
Livingston JA; Hess KR; Naing A; Hong DS; Patel S; Benjamin RS; Ludwig JA; Conley A; Herzog CE; Anderson P; Meric-Bernstam F; Kurzrock R; Subbiah V
Oncotarget; 2016 Sep; 7(39):64421-64430. PubMed ID: 27486883
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial outcomes in older patients with advanced solid tumours.
Khan KH; Yap TA; Ring A; Molife LR; Bodla S; Thomas K; Zivi A; Smith A; Judson I; Banerji U; de Bono JS; Kaye SB
Br J Cancer; 2016 Feb; 114(3):262-8. PubMed ID: 26757260
[TBL] [Abstract][Full Text] [Related]
6. Lymph node metastases of adenocarcinoma of the esophagus and esophagogastric junction.
Zhang X; Watson DI; Jamieson GG
Chin Med J (Engl); 2007 Dec; 120(24):2268-70. PubMed ID: 18167216
[TBL] [Abstract][Full Text] [Related]
7. A reliable risk score for stage IV esophagogastric cancer.
Blank S; Lordick F; Dobritz M; Grenacher L; Burian M; Langer R; Roth W; Schaible A; Becker K; Bläker H; Sisic L; Stange A; Compani P; Schulze-Bergkamen H; Jäger D; Büchler M; Siewert JR; Ott K
Eur J Surg Oncol; 2013 Aug; 39(8):823-30. PubMed ID: 23375470
[TBL] [Abstract][Full Text] [Related]
8. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials.
Alhalabi O; Hahn AW; Msaouel P; Meric-Bernstam F; Wilson N; Naing A; Piha-Paul S; Janku F; Pant S; Yap TA; Hong DS; Fu S; Karp D; Beltran K; Campbell E; Le H; Campbell MT; Shah A; Tannir NM; Siefker-Radtke A; Gao J; Roszik J; Subbiah V
Clin Genitourin Cancer; 2022 Feb; 20(1):e16-e24. PubMed ID: 34362693
[TBL] [Abstract][Full Text] [Related]
9. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg.
Berger AK; Zschaebitz S; Komander C; Jäger D; Haag GM
World J Gastroenterol; 2015 Apr; 21(16):4911-8. PubMed ID: 25945004
[TBL] [Abstract][Full Text] [Related]
10. The neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials.
Kumar R; Geuna E; Michalarea V; Guardascione M; Naumann U; Lorente D; Kaye SB; de Bono JS
Br J Cancer; 2015 Mar; 112(7):1157-65. PubMed ID: 25719834
[TBL] [Abstract][Full Text] [Related]
11. Do elderly patients benefit from enrollment into Phase I Trials?
Tai WM; Lim C; Ahmad A; Ong WS; Choo SP; Lim WT; Tan EH; Kanesvaran R; Tan DS
J Geriatr Oncol; 2015 May; 6(3):241-8. PubMed ID: 25779876
[TBL] [Abstract][Full Text] [Related]
12. Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.
George A; Kristeleit R; Rafii S; Michie CO; Bowen R; Michalarea V; van Hagen T; Wong M; Rallis G; Molife LR; Lopez J; Banerji U; Banerjee SN; Gore ME; de Bono JS; Kaye SB; Yap TA
Eur J Cancer; 2017 May; 76():52-59. PubMed ID: 28273485
[TBL] [Abstract][Full Text] [Related]
13. Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials.
Olmos D; Baird RD; Yap TA; Massard C; Pope L; Sandhu SK; Attard G; Dukes J; Papadatos-Pastos D; Grainger P; Kaye SB; de Bono JS
Clin Cancer Res; 2011 Aug; 17(15):5188-96. PubMed ID: 21531820
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study.
Carceller F; Bautista FJ; Jiménez I; Hladun-Álvaro R; Giraud C; Bergamaschi L; Dandapani M; Aerts I; Doz F; Frappaz D; Casanova M; Morland B; Hargrave DR; Marshall LV; Vassal G; Pearson AD; Geoerger B; Moreno L
Eur J Cancer; 2016 Nov; 67():130-140. PubMed ID: 27662616
[TBL] [Abstract][Full Text] [Related]
15. Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience.
Wheler J; Tsimberidou AM; Hong D; Naing A; Falchook G; Piha-Paul S; Fu S; Moulder S; Stephen B; Wen S; Kurzrock R
Clin Cancer Res; 2012 May; 18(10):2922-9. PubMed ID: 22452943
[TBL] [Abstract][Full Text] [Related]
16. Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Prognostic Markers for Extensive Disease of Small Cell Lung Cancer.
Minami S; Ihara S; Komuta K
World J Oncol; 2020 Jun; 11(3):98-105. PubMed ID: 32494316
[TBL] [Abstract][Full Text] [Related]
17. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?
Heger U; Blank S; Wiecha C; Langer R; Weichert W; Lordick F; Bruckner T; Dobritz M; Burian M; Springfeld C; Grenacher L; Siewert JR; Büchler M; Ott K
Ann Surg Oncol; 2014 May; 21(5):1739-48. PubMed ID: 24419755
[TBL] [Abstract][Full Text] [Related]
18. [Early phase trials at the "Institut de cancérologie de l'Ouest": Clinical outcome and validation of prognostic scores].
Greilsamer C; Campion L; Cabart M; Gourmelon C; Senellart H; Bennouna J
Bull Cancer; 2018 Oct; 105(10):896-906. PubMed ID: 30348261
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Significance of Sarcopenia in Patients with Esophagogastric Junction Cancer or Upper Gastric Cancer.
Kudou K; Saeki H; Nakashima Y; Edahiro K; Korehisa S; Taniguchi D; Tsutsumi R; Nishimura S; Nakaji Y; Akiyama S; Tajiri H; Nakanishi R; Kurashige J; Sugiyama M; Oki E; Maehara Y
Ann Surg Oncol; 2017 Jul; 24(7):1804-1810. PubMed ID: 28224363
[TBL] [Abstract][Full Text] [Related]
20. Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer.
Minami S; Ihara S; Ikuta S; Komuta K
World J Oncol; 2019 Apr; 10(2):90-100. PubMed ID: 31068989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
